Other

Junten Bio Co., Ltd.

Sumitomo Electric Industries, Limited

Japan Science and Technology Agency

Kanebo, Limited

The Green Cross Corporation

Yoshitomi Pharmaceutical Industries, Ltd.

Meiji Co., Ltd.

Ko Okumura

Chisei Ra

Motomi Nakata

Hideo Yagita

Kazuyoshi Takeda

Koichiro Uchida

Koji Naito

Minoru Hirama

Nobuhiko Kayagaki

Hiroaki Maeda

Hiroyuki Itou

Masatsugu Shimomura

Hirofumi Higuchi

Yasuyuki Eda

Seiya Makino

Shuji Ikegami

Takahiko Hariyama

Yukio Asami

Daisuke Ishii

Masayuki Kawakami

Hiroshi Kano

Yoshitaka Ushio

Jun Henmi

Hiroyasu Nakano

Isao Nagaoka

Keisuke Sawaki

Sachio Kawai

Ken-ichiro Seino

Yoshio Suzuki

Yukihito Hasunuma

Hiroshi Eto

Yukiyoshi Yanagihara

Sachiko Miyake

Tadashi Nishida

Marie Tani

Ryu Maeda

The present disclosure provides a pharmaceutical composition for antigen-specific immune tolerance or immune present suppression. The disclosure provides pharmaceutical composition comprising a CD-positive anergy T cell and a CD-positive anergy T cell. In some embodiments, the anergy T cell is induced by an antibody capable of inhibiting the interaction between CDand/or CDand CD. In a specific embodiment, the pharmaceutical composition May additionally comprise a regulatory T cell (e.g., a FOXP-positive CD-positive CD-positive T cell).

Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte

The present disclosure provides a novel technique relating to immunological tolerance. More specifically, the present inventor found for the first time that, in a technique for inducing immunological tolerance by administering an organ transplantation patient (a recipient) a cell preparation containing cells in which anergy is induced by an inhibitor inhibiting the interaction between CD80/CD86 and CD28, the immunological tolerance continues even after the disappearance of the cells derived from the cell preparation from the recipient (infectious immunological tolerance). Further, the present inventor proved that such a cell preparation can elicit immunological tolerance against immunological rejection caused by allergy, iPS cells, etc. or cells, tissues or organs derived therefrom.

Method for eliciting infectious immunological tolerance

The present disclosure provides an antibody for inducing immune tolerance, an induced lymphocyte, and a cell therapy agent therapeutic method using the induced lymphocyte. Specifically, the present disclosure provides an antibody that inhibits the interaction between CD80 and/or CD86 expressed on the surface of a certain cell and CD28 expressed on the surface of another cell, and substantially does not induce immune activation-induced cytokines. In a specific embodiment, the Fc portion of the antibody substantially does not produce the immune activation-induced cytokines.

Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte

A combined-blade open flow path device is a fluid flow path device where flow paths are adjacent to each other. The combined-blade open flow path device comprises a substrate configured to constitute a bottom portion of the flow paths; and blades erected on a surface of the substrate, the blades being configured to constitute side walls of the flow paths, wherein the blades are erected in groups, each of the groups extending from an upstream side to a downstream side in a flow direction of a fluid with a space between each of the blades in the flow direction of the fluid in each of the groups for making conduction of the fluid between the adjacent flow paths possible, and wherein one end of one of the flow paths is configured to be in contact with the fluid and is configured to make a flow of the fluid possible.

Combined-blade open flow path device and joined body thereof

The present invention addresses the problem of providing an antibody titer-increasing agent, such as an adjuvant, capable of sustaining an effect achieved by, for example, vaccination, which is an antibody titer-increasing agent such as an adjuvant that is safe, convenient and economical and can be easily taken irrespective of age, and a method for manufacturing the same. A method for increasing an antibody titer and a method for enhancing the effect of a vaccine, each method comprising usingsubspeciesOLL1073R-1 or a culture thereof; and an antibody titer-increasing agent such as an adjuvant that comprisessubspeciesOLL1073R-1 or a culture thereof.

Antibody titer-increasing agent using lactic acid bacterium

The invention provides monoclonal antibodies, which specifically react with a Fas ligand, or active fragments thereof, a production process of the monoclonal antibodies, which specifically react with a Fas ligand, hybridomas separately producing a monoclonal antibody, which specifically reacts with a Fas ligand present on a cell surface, a method of detecting a Fas ligand in a solution, and a kit for use in detecting a Fas ligand, comprising plurality of monoclonal antibodies against Fas ligand in combination.

Monoclonal antibody reacting specifically reacting with Fas ligand and production process thereof

Novel humanized immunoglobulins and active fragments thereof which are specifically reactive to Fas ligand are provided, and a site on Fas ligand which is important to inhibit apoptosis induced by the Fas-Fas ligand interaction against Fas-expressing cells is demonstrated. The novel humanized immunoglobulins and active fragments thereof which are specifically reactive to Fas ligand are prepared from hybridomas which produce monoclonal antibodies specifically reactive to Fas ligand, via recombinant DNA techniques. The humanized immunoglobulins can inhibit the physiological reactions between Fas ligand and Fas such as apoptosis. Further, identification of the site which is on Fas ligand and responsible for apoptosis induction allows creation of recombinant proteins or peptides which are specifically reactive to the amino acids within the site so as to inhibit apoptosis, and to find new therapeutic or diagnostic agents.

Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand

This invention relates to a TRAF family molecule, a polynucleotide encoding the molecules, an antibody against the molecules, and an antisense polynucleotide of the molecule. Employing an oligo-DNA primer capable of amplifying the most highly conserved region of a known TRAF family molecule, PCR was performed with the aid of cDNA derived from various cell strains and tissues as a template. Thus, the base sequence of the gene of an unknown TRAF family molecule and the amino acid sequence of the TRAF family molecule encoded by the gene were elucidated. An antibody against the molecule was also prepared. By utilizing the TRAF family molecules, genes thereof, and antibodies against the molecules, there are provided methods for elucidating the functions of the proteins and methods for elucidating the signal transduction system of the TNF-R family involving the molecules, as well as probes for research and diagosis, which suggest applications in therapeutic agents.

TRAF family molecules, polynucleotides encoding them, and antibodies against them

Disclosed is an antiallergic composition comprising, as an active ingredient, a peptide which is capable of binding to human IgE, more specifically the high-affinity immunoglobulin E receptor .alpha. chain or a soluble fragment, which is capable of binding to human IgE, or the high-affinity immunoglobulin E receptor .alpha. chain. The composition is clinically useful for blocking allergic responses.

Antiallergic compostion

Antibodies to Fas-L for treatment of hepatitis

Disclosed is an antiallergic composition comprising, as an active ingredient, a peptide which is capable of binding to human IgE, more specifically the high-affinity immunoglobulin E receptor .alpha.-chain or a soluble fragment, which is capable of binding to human IgE, or the high-affinity immunoglobulin E receptor .alpha.-chain. The composition is clinically useful for blocking allergic responses. An animal model for use in the screening of prophylactic and therapeutic compositions for IgE-related diseases is also disclosed.

Immunoglobulin E receptor .alpha.-chain inhibits IgE production and

Drug for the treatment of rheumatoid arthritis

A monoclonal antibody specifically reactive to hamster immunoglobulins, a hybridoma producing said monoclonal antibody, and an immunoassay utilizing said monoclonal antibody are provided. The monoclonal antibody is useful in an immunoassay as a secondary antibody to a hamster-derived primary antibody or antiserum raised against various antigens.

Antibody reactive to hamster immunoglobulins and assay using same

Growing community of inventors

Tokyo, Japan

Ko Okumura